Why Choose a Registered Pharmacy for Weight Loss Treatment?
GPhC Registration: Your Safety Assurance for Mounjaro vs Wegovy
When comparing Mounjaro vs Wegovy for weight loss, choosing a GPhC-registered pharmacy ensures you receive genuine medicines through proper regulatory channels. EverydayMeds holds registration #9012878, verifiable through pharmacyregulation.org, guaranteeing our Leicester-based facility meets stringent UK standards. Our MHRA-regulated supply chain provides complete traceability from manufacturer to your door, essential for prescription-only medicines requiring cold-chain storage.
Licensed UK prescribers review every consultation for Mounjaro vs Wegovy comparisons, ensuring appropriate treatment selection based on your medical history and weight management goals. This regulatory oversight protects patients from counterfeit medicines whilst ensuring proper dose escalation protocols are followed for both semaglutide and tirzepatide treatments.
Pricing Transparency: Mounjaro vs Wegovy Costs Compared
Wegovy pricing at EverydayMeds starts from £79.99 for the 0.25mg starter dose, with new customers using code FIRST40 applied at checkout. The full dose escalation costs £94.99 (0.5mg), £99.99 (1mg), £139.99 (1.7mg), and £209.99 for the 2.4mg maintenance dose. Our bundled options like the Intro Duo (0.25mg & 0.5mg) cost £169.99, providing convenient multi-month supply.
Mounjaro pricing follows a similar structure but remains limited in UK availability compared to Wegovy's established supply chain. Both treatments require identical clinical assessment processes, with returning customers benefiting from code DOSE25 at checkout. Our transparent pricing includes all consultation fees, prescriber review, and next-day delivery costs.
Clinical Evidence: Understanding Mounjaro vs Wegovy Effectiveness
Wegovy's clinical evidence comes primarily from the STEP trial programme, with Wilding et al. (NEJM, 2021) demonstrating approximately 15% average weight loss at 68 weeks when used alongside diet and exercise. These results reflect treatment in controlled clinical conditions with intensive lifestyle support.
Mounjaro's evidence derives from SURMOUNT trials showing similar efficacy patterns, though direct head-to-head comparisons remain limited due to different trial designs and patient populations. Both prescription-only medicines work through incretin pathways but utilise different receptor mechanisms.
How Wegovy Works: GLP-1 Mechanism for Weight Management
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural fullness hormone produced in the intestine after eating. This mechanism reduces appetite by acting on brain centres controlling food intake, promoting earlier satiety signals during meals. The treatment may help reduce food cravings and portion sizes when used alongside a reduced-calorie diet and increased physical activity. Clinical studies suggest this approach supports sustainable weight management through behavioural changes rather than forced restriction. Patients typically notice appetite changes within the first few weeks of treatment, though individual responses vary considerably.
Streamlined Ordering: From Assessment to Delivery
Our 3-minute online clinical assessment covers medical history, current medications, and weight management goals relevant to both Mounjaro vs Wegovy selection. Licensed UK prescribers review applications within 3 working days (24-hour express available), ensuring appropriate treatment choice based on individual circumstances. Once approved, medicines dispatch via next-day delivery using temperature-controlled packaging maintaining cold-chain integrity. Our Leicester facility operates full traceability systems, recording every step from prescription to delivery. Patient support continues throughout treatment with dose escalation guidance and ongoing clinical monitoring as required.
Storage Advantages: Wegovy's Practical Benefits
Wegovy offers superior storage flexibility compared to Mounjaro, remaining stable for 6 weeks at room temperature below 30°C once removed from refrigeration. This advantage benefits frequent travellers or those with limited fridge space, whilst Mounjaro requires return to refrigeration within 21 days. Both use pre-filled FlexTouch pen systems requiring identical injection techniques and disposal methods. Dose escalation protocols differ slightly, with Wegovy following a standardised 4-week progression schedule. Patients must complete the full escalation sequence regardless of which treatment they choose, as skipping doses increases side effect risks.
Regulatory Compliance: Why Pharmacy Registration Matters
GPhC registration #9012878 ensures EverydayMeds maintains pharmaceutical standards essential for weight management treatments requiring clinical oversight. Our Leicester-based facility undergoes regular inspections covering storage conditions, prescriber qualifications, and patient safety protocols specific to prescription-only medicines. This regulatory framework protects against counterfeit products increasingly common in unregulated weight loss markets.
Licensed prescribers must verify patient suitability for both Mounjaro vs Wegovy treatments, considering BMI requirements, medical contraindications, and realistic weight management expectations. This clinical governance ensures patients receive appropriate treatment selection rather than simply purchasing products online without proper medical oversight.
Start Your Weight Management Journey Today
Both Wegovy and Mounjaro are available through EverydayMeds with identical clinical assessment standards and next-day delivery service. New customers benefit from code FIRST40 applied at checkout, whilst returning patients use DOSE25 for continued savings. Our prescriber team helps determine which treatment suits your individual circumstances through comprehensive consultation review. Begin your clinical assessment today at our secure online platform, backed by GPhC registration #9012878 and full MHRA compliance. Your weight management journey deserves proper pharmaceutical support from qualified UK professionals.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
